Melissa Cummings Sells 9,578 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) COO Melissa Cummings sold 9,578 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the transaction, the chief operating officer owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. The trade was a 11.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

Shares of PGNY opened at $24.88 on Friday. The company has a market cap of $1.95 billion, a P/E ratio of 32.31, a PEG ratio of 1.31 and a beta of 0.91. The stock has a fifty day moving average price of $19.06 and a 200 day moving average price of $22.03. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The firm had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The firm’s revenue was down 26.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts anticipate that Progyny, Inc. will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after purchasing an additional 235,513 shares in the last quarter. State Street Corp grew its stake in shares of Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock worth $75,838,000 after purchasing an additional 44,642 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in shares of Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after purchasing an additional 1,621,688 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Progyny by 37.6% in the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. KeyCorp lowered their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 price target on shares of Progyny in a research report on Friday, March 6th. Citizens Jmp increased their price target on Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research note on Monday, May 11th. Finally, Citigroup reissued an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.